Latest 10-K annual reports

Vaccinex's 10-K filing reveals a clinical-stage biotech company prioritizing Alzheimer's disease treatment while navigating financial challenges and strategic partnerships.

GiveMePower Corporation's 10-K filing details a strategic shift towards fintech, a pause in real estate acquisitions due to interest rate concerns, and ongoing efforts to empower black communities through financial tools and resources.

SMC Entertainment's 10-K filing reveals a substantial net loss of $8.43 million for 2024 and expresses substantial doubt about the company's ability to continue as a going concern.

Micromobility.com transitions to a technology-focused enterprise, providing software development and business services, while reporting financial results for the year ended December 31, 2024.

Moatable, Inc. saw its net loss decrease in FY2024, driven by growth in its SaaS businesses, Lofty and Trucker Path.

Golden Minerals reports a net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Vestiage, Inc. reports a net loss of $52,675 for the year ended December 31, 2024, and expresses substantial doubt about its ability to continue as a going concern.

Dream Homes & Development Corporation reports a net income of $875,966 for 2024, shifting its focus towards build-to-lease properties and improved lots for sale to capitalize on market trends.

Selectis Health saw a revenue increase in 2024, but faces significant financial challenges raising substantial doubt about its ability to continue as a going concern.

PrimeEnergy Resources Corporation's 10-K filing reveals a significant increase in oil and gas production and proved reserves for the fiscal year ended December 31, 2024, driven by horizontal drilling activities, primarily in the Midland Basin of West Texas.

FOXO Technologies amends its termination agreement with KR8 AI to clarify the scope of the termination, focusing on financial obligations rather than the entire agreement.

TriSalus Life Sciences reports a 59% increase in revenue for 2024, driven by its TriNav Infusion System, while continuing to develop its immunotherapeutic, nelitolimod.

SUNation Energy's 10-K filing reveals delisting concerns, material weaknesses in internal controls, and a strategic shift towards Bitcoin amidst ongoing financial challenges.

Yuenglings Ice Cream Corporation, rebranding as a technology holding company, reports a net profit of $4.39 million for 2024, driven by fair market value changes and debt extinguishment gains, while strategically divesting its ice cream assets.

Oncotelic Therapeutics' 2024 annual report details ongoing efforts to develop cancer treatments, manage financial constraints, and advance strategic partnerships, particularly through its joint venture GMP Biotechnology.

Eyenovia is exploring strategic alternatives and cutting costs after a negative clinical trial result, raising concerns about its ability to continue as a going concern.

Royalty Management Holding Corporation files an amendment to its 2024 annual report to include a compensation clawback policy.

Balance Labs, a consulting firm for startups, reported a net loss of $528,223 for the year ended December 31, 2024, and its independent auditor has raised substantial doubt about its ability to continue as a going concern.

Banzai International, Inc. details its financial performance for fiscal year 2024, highlighting strategic acquisitions, Nasdaq listing compliance, and ongoing efforts to manage operating losses and enhance shareholder value.

Nauticus Robotics reports a substantial net loss for 2024, signaling a challenging year as the company transitions towards commercializing its autonomous subsea robotic solutions.

LanzaTech Global's FY2024 results reveal ongoing net losses and substantial doubt about its ability to continue as a going concern, while the company evaluates a non-binding take-private proposal from Carbon Direct Capital.

Cactus Acquisition Corp. 1 Ltd.'s annual report reveals delisting from Nasdaq, a business combination agreement with Tembo e-LV B.V., and substantial doubt about its ability to continue as a going concern.

AppYea Inc.'s Form 10-K reveals a significant increase in net loss for the fiscal year ended December 31, 2024, and raises substantial doubt about the company's ability to continue as a going concern.

Iveda Solutions reports a slight decrease in revenue for 2024, accompanied by an increased net loss, as the company navigates a strategic shift towards AI and IoT technologies.

Vivakor's 2024 annual report shows revenue growth driven by acquisitions, but significant net losses and an accumulated deficit raise concerns about the company's ability to continue as a going concern.

TransCode Therapeutics faces financial hurdles but progresses with clinical trials and preclinical programs in RNA-based cancer therapies.

Toppoint Holdings Inc.'s 2024 annual report reveals a revenue decrease due to lower scrap paper export volumes, offset by strategic expansions and new partnerships.

Cosmos Health Inc. reports a net loss of $16.18 million on revenue of $54.43 million for fiscal year 2024, while addressing concerns about its ability to continue as a going concern.

ESG Inc. reports a 70.2% increase in net operating revenue for the year ended December 31, 2024, driven by expanded capacity and sales of Phase III compost and processed mushroom seasoning powder.

Akari Therapeutics shifts focus to oncology with its ADC platform following a merger, while acknowledging significant financial risks and material weaknesses in internal controls in its recent 10-K filing.